Primary progressive aphasia (PPA) is a clinical syndrome characterized by a progressive language disorder with preservation of memory, visuospatial skills, and reasoning functions in the initial stages. 1 There are currently no Food and Drug Administration approved treatments for PPA or other forms of non-Alzheimer dementia. We previously showed that bromocriptine did not produce significant effects on language measures during a 15-week double-blind cross-over study. 2 A trial of galantamine was also mostly negative despite a trend suggesting that aphasia scores were more stable in the treatment than the placebo group. 3 Boxer et al 4 recently published an open-label study of memantine in 3 non-Alzheimer clinical dementia syndromes, including 2 PPA subtypes known as progressive nonfluent aphasia and semantic dementia. 5 The progressive nonfluent aphasia patients showed relative stability on the Alzheimer Disease Assessment Scale-Cognitive over the 52 weeks of the study, whereas the semantic dementia patients declined.
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We conducted a double-blind, placebo controlled trial with 18 PPA subjects with mild-to-moderate disease severity (mean Western Aphasia Battery 6 aphasia quotient = 72.4). Patients were randomly assigned to receive memantine or placebo for 26 weeks and were then crossed over to the other arm. Subjects received 5 mg memantine daily (or placebo) for the first week and were titrated up by 5 mg memantine per day every week over the next 3 weeks until reaching the target dose of 20 mg memantine in 2 divided doses per day. Subjects remained at 20 mg/d for the next 5 months. Assessment of language, behavior, and activities of daily living was performed at baseline and at the end of the 6-month period. The washout phase consisted of reducing the memantine dose by 5 mg/d/wk over a 4-week period followed by 2 weeks of no medication. Subjects were then crossed over to the other arm of the study. Nine subjects completed the entire trial. Of the 9 subjects who discontinued, 7 were unable to return for follow-up testing because of living out of state and 2 wanted to receive a prescription for memantine. None of the subjects experienced any adverse events related to the study drug.
All data were analyzed using a repeated measures analysis of variance to determine whether the change from baseline to endpoint was different between the drug and placebo phases. Although none of the measures showed a significant difference in change between placebo and drug phases, there was a trend for a smaller degree of decline on the Western Aphasia Battery total aphasia quotient in the drug group (À 2.13) than in the placebo group (À 6.42), a mean difference in change of 4.29. Power calculations based on these data indicate that a sample of size 14 has 80% power to detect a mean difference in change of 4.0 units on the aphasia quotient in future trials. Consistent with the Boxer et al study, these results provide support for the consideration of largerscale randomized controlled trials in PPA. 
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Progranulin Mutations are a Common Cause of FTLD in Northern Italy
To the Editor:
Once considered a rare disorder, frontotemporal lobar degeneration (FT LD) is now recognized as a common cause of early-onset dementia. FTLD has a strong genetic component, with up to 50% of cases being caused by mutation. So far 4 disease causing genes have been identified, most recently the progranulin gene (PGRN), which was shown to be the most frequent genetic determinant: 68 mutations have been described in 208 families which account for 5% to 10% of FTLD cases worldwide (http://www.molgen.ua.ac.be/FTD mutat ions/). In subpopulations of patients with familial FTLD, the PGRN mutation frequency can be up to 26%. 1 We read with interest the debate on the frequency of mutations in PGRN gene in Italian FTLD patients. 2, 3 Tremolizzo et al estimated the contribution of the PGRN and MAPT mutations to FTLD in a patients cohort enrolled in the area of Monza-Brianza (Northern Italy): although no mutations were detected in MAPT, a higher than expected rate of mutations in the PGRN gene (9%) was found. The mutation detected in these patients was a c.813_816del-CACT mutation (Leu271LeufsX10) earlier identified by our group in 2 large Italian pedigrees. 4 We recently reported that the PGRN c.813_816delCACT mutation is one of the most common FTLD associated mutations worldwide. 5 Thus, the finding from Tremolizzo et al is in agreement with our data.
Circulating PGRN protein is a highly accurate biomarker for the detection and prediction of neurodegeneration caused by PGRN loss-of-function mutations. 6, 7 Using the plasma progranulin dosage, we are presently screening patients who come to the attention of the Memory Clinic, IRCCS ''Centro S. Giovanni di Dio-Fatebenefratelli,'' Brescia, Italy. To date, we have analyzed a total of 205 FTLD patients (familial n = 109, sporadic n = 96). Mean age at clinical evaluation (± SD) was 66.9 years (± 9.7); mean age at disease onset was 63.4 years (± 10.7). The PGRN Leu271-LeufsX10 mutation was detected in 22 unrelated familial FTLD patients (20.2%, 22 of 109) and 5 sporadic FTLD cases (5.2%, 5 of 96) leading to a prevalence of 13.2% within the Brescia cohort. By comparison, the total detected PGRN mutations, frequencies were 24.8% for familial FTLD and 15.6% for FTLD overall. In addition, plasma progranulin dosage allowed the identification of PGRN mutations in 2 patients presenting with Lewy Body dementia and in 2 patients affected with Alzheimer disease and Vascular dementia, respectively. Given the role of PGRN as a major genetic determinant of FTLD and related disorders, we expect that in the next decade the progranulin plasma or serum dosage will be translated into a clinically valid, standardized test that is incorporated in the diagnostic work-up of dementia. 
Can Tetrathiomolybdate be a Potential Agent Against Alzheimer Disease? A Hypothesis Based on Abnormal Copper Homeostasis in Brain
Alzheimer Disease (AD) is a progressive brain disease characterized by impairment of memory and cognitive dysfunction. The prevalence and public health importance of AD is increasing with the number of older individuals world-wide. 1 Although AD researchers have made great progress in understanding the pathophysiology of AD, most of currently available drugs focus on symptom relief and there is need for new approaches to drug therapies that target the underlying pathophysiology of the disease. 2 We hypothesize that abnormal copper metabolism in AD may be a new area of treatment opportunity.
ABNORMAL COPPER HOMEOSTASIS IN AD
Copper (Cu) homeostasis is essential for the survival of all organisms. Although its deficiency incapacitates different cellular functions, extra intracellular-free Cu results in cellular toxicity. 3 In recent decades, relationships between abnormal copper metabolism and various neurologic disorders, including Huntington disease, Amyotrophic lateral sclerosis, Parkinson disease, and AD, have been established. [4] [5] [6] It is now well-described that the transport of copper into the brain is complex and involves numerous cofactors, including amyloid precursor protein, A peptide, and cholesterol. 7 In conditions in which the pH of brain becomes mildly acidic, such as aged brain or in the presence of inflammation, Cu2+ induces formation and aggregation of insoluble Ab. Therefore, balance in Cu concentration, and the maintenance of normal pH, may be crucial to prevention of Ab aggregation and amyloid formation. 8 Furthermore, it seems that Cu2+ disturbs Ab clearance in brain through promoting highcholesterol levels, which is an important factor in Ab deposition. 9 The high metabolic rate of brain and its limited antioxidant systems makes the brain an organ susceptible to oxidative stress, and oxidative stress plays a significant role in the cellular dysfunction and degeneration occurring in AD. 10 In this setting, by virtue of the redox-active nature of Cu, defective regulation of this metal in brain can lead to reaction with O 2 and the production of reactive oxygen species (ROS), resulting in neuronal toxicity. 11
TETRATHIOMOLYBDATE AND NEUROLOGIC DISORDERS
Tetrathiomolybdate (TM) is a recognized treatment for patients with Wilson disease presenting with neurologic disease. It is also a novel anticancer and antiangiogenic agent, which acts by the transcription factor nuclear factor kB (NF-kB) inhibition and copper chelation. 12 TM has a highchelating selectivity for copper ions and has a high central nervous system (CNS) penetration, and the ability to chelate intracellular and extracellular copper ions. This makes the drug superior to other copper chelating agents for treatment of CNS involvement of Wilson disease. 13 In addition to the mentioned applications of TM in medicine, recent investigations find that, owing to the unique properties of TM, this agent may be a good candidate for treatment of different neurologic disorders such as Huntington disease, multiple sclerosis, and amyotrophic lateral sclerosis. 5, 6, 14 
HYPOTHESIS
There is growing body of evidence, which indicate that metal ions play an important role in the pathogenesis of neurodegenerative disorders, especially AD. 15 On the basis of the presented reasons, it seems that increased amount of Cu2+ in aged brain promotes pathologic changes of AD and application of Cu2+ chelators, which have good CNS penetration, can be a promising therapeutic strategy.
In addition to good CNS penetration and strong Cu2+ chelating activity, TM has some additional properties which make it a potential AD therapeutic agent. For example, TM can inhibit NF-kB, which is widely expressed in the nervous system, and its immunoreactivity has been observed in AD brains in neurons near diffuse bamyloid plaques. 16 It is also known that NF-kB inhibitors prevent AD pathologic changes in animal models. 17 The potential superiority of TM over other copper chelators in the treatment of AD can also be explained by its effect on Superoxide dismutase enzyme (SOD). SOD is a key antioxidant enzyme that catalyzes the disproportion of superoxide radicals into molecular oxygen and hydrogen peroxide which further should be detoxified by Catalase enzyme. Any increase in SOD catalytic activity produces an excess of hydrogen peroxide, which exceeds beyond the ability of tissue catalases to detoxify this product of SOD leading to oxidative damage to the tissue. 18 SOD is proven to be the major target of oxidative damage in AD brain.
